Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018

Sandoz needs to do another study to satisfy FDA, while Amgen says it faces a slow pace of patent litigation with AbbVie.

DNA

There's still only one biosimilar on the US market, but the third quarter earnings calls this year may have marked the point where updates about them became routine, with firms discussing the products just as they would any pipeline project or potential competitor.

Novartis AG, for one, confirmed during its third quarter earnings call that its application for a biosimilar version of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics